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Rami B. Ibrahim, Muneer H. Abidi, Simon M. Cronin, Lawrence G. Lum, Zaid Al-Kadhimi,
Voravit Ratanatharathorn, Joseph P. UbertiFor over a decade, nonabsorbable corticosteroids have been employed in the treatment of gastrointestinal
graft-versus-host-disease (GVHD) in hematopoietic stem cell transplant (HSCT), as monotherapy or in com-
bination with systemic corticosteroids. The majority of the evidence showing a favorable outcome consisted
of case series, small phase II trials and a large randomized phase III trial. The 2 most commonly studied mol-
ecules were oral budesonide and beclomethasone diproprionate. Although these reports hint at some ben-
efit with the local treatment strategy, their methodologic inconsistencies preclude meaningful adoption to
everyday clinical practice. This review evaluates the current evidence of nonabsorbable corticosteroids in
HSCTand sets forth recommendations for future trials with these agents.
Biol Blood Marrow Transplant 15: 395-405 (2009)  2009 American Society for Blood and Marrow TransplantationKEYWORDS: Budesonide, Beclomethasone dipropionate, Gastrointestinal, GVGD, Transplant, Hematopoi-
eticBACKGROUND
Graft-versus-host-disease (GVHD) is 1 of the most
common complication of allogeneic hematopoietic
stem transplantation (HSCT), and is the leading cause
of morbidity and mortality [1,2]. The initial treatment
of acute GVHD (aGVHD) is systemic corticosteroids,
which yield a complete response in 35% of patients [3-
5]. Immunosuppressants, such as tumor necrosis factor
(TNF) blockers, hold promise, as shown with etaner-
cept when it was combined with systemic corticoste-
roids [6,7]. By in large, the outcome of various
GVHD treatment modalities remains far from satisfac-
tory. Faced with this vexing outcome of aGVHD re-
sponse and also the need to minimize adverse events
caused by protracted use of high-dose systemic cortico-
steroids, nonabsorbable corticosteroids were explored
over the last decade for the treatment of gastrointesti-
nal (GI) GVHD in HSCT. The reason for the use of
nonabsorbable corticosteroids was their success in
inflammatory bowel disease (IBD), a disease with an
overlapping pathphysiology with GI GVHD [3,8]. InKarmanos Cancer Institute and Wayne State University,
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6/j.bbmt.2008.12.487addition, the GI tract has long been postulated to
have a major role in the amplification of immunopatho-
genesis of GVHD via ‘‘cytokine storms’’ [9]. This
review will evaluate the use of nonabsorbable cortico-
steroids in the treatment of GI GVHD.
Beclomethasone
Oral beclomethasone diproprionate (BDP) is a di-
ester of beclomethasone, a synthetic corticosteroid
chemically related to dexamethasone [10]. It is hydro-
lyzed to an active metabolite, beclomethasone 17-mo-
noproprionate (17-BMP), by esterase in the intestinal
fluid and mucosal epithelial cells. Then, it is slowly
transformed to alcohol. Following its oral administra-
tion, no BDP is detected in the plasma [10]. The oral
bioavailability of 17-BMP is 41% (90% confidence in-
terval [CI]: 31%-54%) and elimination halflife is 8.8
hours (range: 4.9-47.7 hours). Oral BDP given as a
gelation capsule distributes to the mucosa of upper
GI tract with 14% of the dose recovered in ileostomy
effluent of normal human volunteers. Forty-three
percent of the enteric-coated BDP-formulation is re-
covered in ileostomy effluent after 8 hours [10]. Area
under the curve (AUC), expressed as unbound prednis-
olone equivalents, show that systemic 17-BMP (at 2-
mg oral BDP dose) was similar to that of a repeated
dosing schedule of oral prednisone 2.5 mg and less
than intravenous (i.v.) dexamethasone 1 mg [10].
Clinical Trials
In the first trial evaluating nonabsorbable steroids
in HSCT patients, oral BDP was given as a plain395
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28 days in the treatment of intestinal GVHD [11]. Pa-
tients with active systemic or enteric infection at the
time of diagnosis and patients receiving acid suppress-
ing agents were excluded. The primary endpoint was an
improvement in caloric intake to.80% of daily caloric
requirements or a decrease in stool volume from.400
mL/day to \200 mL/day over 28 days. Time from
HSCT to enrollment was 58 days (range: 21-231
days). Twenty-three patients received the drug as
monotherapy and 17 patients in combination with
prednisone. BDP was added to the latter group when
it did not respond to a 7-day systemic steroids course.
Response rates were 77% for the monotherapy group
and 64% in the combination group. Adrenal suppres-
sion was assessed in 15 patients who received BDP
over 28 days: 9 (60%) had evidence of predefined
biochemical criteria for adrenal suppression using
ACTH suppression test; however, none exhibited clin-
ical symptoms of adrenal suppression. Nine patients
were withdrawn from the study because of infection
(4 patients in the BDP monotherapy group). Two pa-
tients withdrew owing to positive surveillance culture
with Corynebacterium colonization in the stool and
Staphylococcus colonization in the throat, leading to bac-
teremia. Noteworthy, responses were independent of
the systemic adrenal suppression effect. This was be-
lieved to be because of the intraepithelial suppression
of T cells by the local effect of BDP/17-BMP and min-
imal systemic effect because the absorbed amount of
17-BMP is small and protein binding and liver clear-
ance are high [10]. The results of this phase I trial sug-
gested that BDP therapy may be effective in the
treatment of mild to moderate upper GI GVHD be-
cause of an optimal delivery of drug per surface area
of mucosa involved.
McDonald et al. [12] reported a phase II trial using
BDP in the treatment of acute intestinal GI GVHD.
Patients receiving systemic corticosteroids, or receiving
acid suppressants drugs and patients with enteric and
systemic infection were excluded. BDP was given as
an enteric-coated and uncoated capsules at 2 mg by
mouth every 6 hours with (n 5 31) and without (n 5
29) prednisone 1 mg/kg daily  10 days followed by
a 1 week taper. The primary endpoint was the ability
to consume 70% or more calories by day 30 of treat-
ment. This was seen in 21 versus 16 patients (71% ver-
sus 41%; P 5 .02) at day 30 in the BDP 1 systemic
steroids combination versus systemic steroids, respec-
tively. Although not a primary endpoint, success rate
was not statistically significant at day 40 (73% versus
42%; P 5 .07) [12]. No enteric infections were ob-
served. The authors concluded that BDP is useful
adjunct to systemic corticosteroids in GI GVHD;
however, they speculated that the 8 mg/day may not
be the maximally tolerated dose. Limitations of the
study were the inclusion of mild forms of GI GVHD(mean diarrhea volume and stool frequency were
160 mL and 1.7 stools/day, respectively, at the time
of randomization), the absence of long-term follow-
up to assess durability of response and adverse events.
Time fromHSCT to enrollment was also not reported.
BDPwas assessed as a single agent in 26HSCTpa-
tients diagnosed with GI aGVHD: 7 patients had
grade I GI GVHD and 19 patients had grade II [13].
BDP 2 mg (4 mL) by mouth every 6 hours was started
on day 47 (range: 17-84 days) after HSCT for a mean
of 28 days (range: 4-60 days). Complete response (CR)
was defined as resolution of GI symptoms and partial
response was defined as improvement of GI score
from baseline (Table 1). Systemic steroids were started
in the event of progression at day 3, absence of any im-
provement at day 7, or absence of CR at day 14. Seven-
teen patients had CR (65.5%) and 3 (11.5%) achieved
partial response (PR). Five patients who reached a CR
relapsed, although 1 of them reached second CR after
a second course of BDP. In sum, CRwasmaintained in
13 of 26 patients (50%). The response rate to 6-meth-
ylprednisolone among patients who did not respond or
maintained CR after BDP reached 69%.There was no
difference between response between grade I and II
aGVHD, full and reduced-intensity (RIC) HSCT,
and depending on presenting symptoms (nausea, vom-
iting, diarrhea), although a trend toward less response
in the diarrhea group was observed. Sixty-nine percent
of patients who did not respond to BDP responded to
systemic steroids. No toxicity was observed during the
entire study period. Limitations of the study were its
uncontrolled design and the nonvalidated response
criteria. Aswithprevious reports, onlymildGIaGVHD
patients were examined. Biochemical assessment of
adrenal function was not done. This was unfortunate,
as the majority of patients (13 of 265 50%) did not re-
ceive systemic corticosteroids, an opportunity allowing
for a better assessment of the adrenal suppressive effect
of oral DBP.
In a single institution phase II trial, Iyer et al. [14]
used BDP for intestinal GI GVHD refractory to calci-
neurin inhibitors and a week-long systemic corticoste-
roids treatments. In contrast to previous work where
BDP was given for 28 days, BDP was given in re-
peated cycles with each cycle defined as 28 days [14].
Patients with active intestinal infection and persistent
vomiting were excluded. Response was defined as com-
plete resolution of GI symptoms and taper of systemic
steroids, and partial response was defined as an im-
provement in GI score and incomplete tapering of sys-
temic steroids. Of the 19 eligible patients, 15 were
evaluable (one patient was excluded because of an ac-
tive enterovirus infection 2 days after BDP initiation).
Thirteen patients had chronic GVHD (cGVHD) and
2 patients had aGVHD. Patients were enrolled in the
study at a median of 265 days (range: 39-1529) after
HSCT. The median number of BDP cycles in all
Table 1. Studies Evaluating BDP and BUD in HSCT
Study Intervention Endpoints Results Comments
Beclomethasone Diproprionate
Baehr et al., 1995 [11] BDP at 8 mg/day in plain gelatin
and enteric coated capsules
(n 5 23) and same BPD regimen +
systemic corticosteroids  28 days
(n 5 17);* randomized controlled study.
Improvement in caloric intake >80% of
daily caloric requirements or a decrease
in stool volume from >400 ml/day to
<200 mL/day over 28 days.
77% (17 of 22) for monotherapy and 64% (9 of 14)
for combination treatment†
- Age range from 5-57 years
- Phase I feasibility trial
McDonald et al., 1998 [12] BDP at 8 mg/day in plain gelatin and
enteric coated capsules (n 5 31)
versus controlled (n 5 29);* randomized
placebo controlled
Ability to consume 70% or more calories
by day 30 of treatment
21 patients (77%) versus 16 patients
(55%) (P 5 .02)
- Few patients with severe GVHD
- One 6-year-old patient was not able to tolerate
treatment
Iyer et al., 2005 [14] BDP at 8 mg/day (n 5 15) in pill or corn
oil emulsion formulations;* single-arm
phase II trial
Improvement in GI score and decrease
in systemic corticosteroids§
9 patients (60%) responded - Chronic GVHD (n 5 13)
- Children were included (n 5 ?; youngest 5)
- A median of 3 cycles were necessary to maintain
or prolong benefit.
Castilla et al., 2006 [13] BDP single agent (n 5 26) in olive oil
formulation; a single arm phase II trial
Improvement in GI symptoms¶ 20 patients (77%) responded - Grade I and II GVHD only
- Adult patients only
- 62% of transplants were reduced intensity
- Responses occurred at a median of 6 days
(range: 3-14 days)
Miura et al., 2006 [15] BDP as a enteric-coated capsules and
aqueous suspension (n 5 5)
monotherapy; case series
Resolution of diarrhea or decrease in
average 3-day average stool volume by
500 mL with clearing of cramps and
bleeding if present.
3/5 patients (60%) responded - Adult patients only
- Grade II and III acute GVHD
- Reduced Cord HSCT
- One patient developed CMV enteritis
Hockenberry et al., 2007 [17] Prednisone at 1-2 mg/kg/day^  10 days
and either oral BDP 8 mg/day (n 5 62)
or placebo (n 5 67) tablets for 50 days.
** Randomized placebo-controlled trial
Phase III
The primary efficacy end point was the
time to treatment failure through
study day 50
The cumulative rate of GVHD-treatment failure
was 31% for BDP arm versus 48% for the control
arm (HR 5 0.63; 95% CI, 0.35-1.13; P 5 .12,
stratified log-rank test).
- Age range was 6-70 years
- Patients with diarrhea >1 L/day were excluded
- 32% of transplants were nonmyeloablative
Budesonide
Bertz et al., 1999 [23] BUD 9 mg/daily (n 5 22) versus
historical control (n 5 19)*
Decrease in stool volume/frequency
of bowel movement
17 patients (77%) versus 6 patients versus
33% showed response (P < .01)
- pH modified BUD was used
- 3 children were included (youngest was 6)
-  47% of patients were Glucksberg’s clinical
grade I/II
- Median time to budesonide clinical response: 12
days (range: 3–28)‡
Andree et al., 2008 [24] BUD at 9 mg/day (n 5 13) in chronic GI
GVHD; retrospective descriptive analysis
Complete resolution of all symptoms
of chronic GVHD
8 (62%) patients achieved complete remission
of GI chronic GVHD ††
- pH modified BUD in 12 patients
- Adult patients
- 85% of transplants were reduced intensity
- Response seen on the first 4 weeks of BUD
GVHD indicates graft-versus-host disease; GI, gastrointestinal; HSCT, hematopoietic stem cell; CMV, cytomegalovirus; HR, hazard ratio.
*In addition to systemic corticosteroids.
†Four patients were excluded from the final analysis.
‡The dose of systemic corticosteroids was also increased when BUD therapy was started.
§GI score: improvement in anorexia, nausea, vomiting, diarrhea, abdominal pain, and weight change of 5% of body weight.
¶Complete response was defined as resolution of GI symptoms with no need of adding systemic steroids. Partial response (PR) was defined as an improvement in GI score from baseline, with improvement consisting
of resolution of diarrhea or a decrease 500 ml in stool volume for 3 days with improvement of abdominal pain or bleeding.
^The initial 16 patients were administered prednisone 2 mg/kg/day for 10 days; the remaining 113 patients received an initial prednisone dose of 1 mg/kg/day after hypothalamic-pituitary-adrenal axis suppression was
observed at the higher dose at the time of study day 50 testing.
**Administered as commercial immediate-release and enteric-coated DBP tablets, each containing 1 mg of BDP. The dosing regimen was 1-mg immediate release and 1-mg enteric-coated tablet taken orally, 4 times
daily (total daily dose, 8 mg BDP).
††GI symptoms consisted mostly of nausea, vomiting, weight loss, and mild-to-moderate diarrhea.
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398 Biol Blood Marrow Transplant 15:395-405, 2009R. B. Ibrahim et al.patients was 2 (range: 1-20), mostly continuous. Three
patients (20%) had a complete response and 6 (40%)
had a partial response rate. Symptom improvement
was seen after 1 cycle in all responders, but a median
of 3 cycles of therapy were necessary to maintain or
prolong the benefit. In responding patients, attempts
were made to taper BDP on day 22 of the second cycle
over a 1-week period. Adrenal axis testing was per-
formed in 5 patients who received more than 6 cycles
of BDP, asymptomatic adrenal insufficiency was found
in 2 patients who received 15 and 20 cycles, respec-
tively. Only 1 of these 2 patient had a remote history
of exposure to systemic corticosteroids. Shortcomings
of the study were its uncontrolled trial design, and the
use of an unvalidated scoring system made it difficult
to compare the severity of GI GVHD and efficacy of
BDP in this patient population with other reports.
A Japanese case series evaluated the use of BDP in
adult patients undergoing RIC cord blood transplanta-
tion as an upfront treatment [15]. Five patients re-
ceived both the enteric coated cellulose capsule and
an aqueous suspension at 2 mg every 6 hours for stage
II and III intestinal aGVHD. Three of 5 patients have
shown a response, whereas the remaining 2 patients re-
sponded to systemic corticosteroid intervention fol-
lowing a week of unsuccessful BDP treatment. BDP
initiation ranged between day126 and153 and lasted
for 7-60 days. One case of cytomegalovirus (CMV)
enteritis was noted with BDP monotherapy. Time to
clinical response was not analyzed. Also, adrenal sup-
pression was not assessed. Oral BDP offered promise
in recurrent small bowel allograft rejection and intesti-
nal GVHD in 3 small bowel transplant patients [16].
In the largest phase III trial to date examining BDP
efficacy in GI GVHD (the ENT00-02 trial), Hocken-
berry et al. [17] used oral commercial BDP (orBec,
DOR BioPharma, Miami, FL; NDA submitted in
1991) using 2 different formulations: immediate-re-
lease and sustained release at 2 mg every 6 hours.
They excluded patients with .1 L/day diarrhea or
skin and/or liver GVHD. The control group consisted
of oral prednisone 1 mg/kg/day for 10 days (n 5 62)
then tapered over 7 days was compared to a similar
prednisone combined with BDP (n 5 67). The pri-
mary endpoint was time to treatment failure through
study day 50. Secondary endpoints included time to
treatment failure 30 days after discontinuation of study
drug and survival at day 200 and 1 year after transplan-
tation. The cumulative rate of GVHD treatment fail-
ure was 31% for BDP arm versus 48% for the
control arm (hazard ratio [HR] 5 0.63; 95% CI,
0.35-1.13; P 5 .12, stratified log-rank test). Excluding
from the analysis 12 patients who experienced treat-
ment failure in the first 10 days, the cumulative rate
of GVHD-treatment failure was significant (HR 5
0.39; 95% CI, 0.19-0.81; P 5 .009, stratified log-
rank test). Mortality at day 200 and 1year was 8%versus 24% (HR 0.33; 95% CI, 0.20-0.69; P 5 .001,
stratified log rank test) and 29% versus 42% (HR
0.54; 95% CI, 0.30-0.99; P 5 .04, stratified log-rank
test) between the intervention and control groups, re-
spectively. Although not specified in the text, BDP pa-
tients had a higher likelihood of having an abnormal
evidence of adrenal suppression than placebo. No
other adverse events were reported.
The results of this study fueled much debate in the
transplant community on several accounts. First, im-
balances between the 2 groups has been suggested to
bias the study results against BDP with more nonmye-
loablativeHSCT and high risk for hematologic relapse
patients in BDP group [10]. Second, the assumption of
proportional hazards in these time-to-event analyses
(relative risk remaining constant over time) was shown
to be in error, as most GVHD treatment failures oc-
curred in the first 10 days. This led to the suggestion
that an analysis on the last day of study drug adminis-
tration and 30 days later (study day 50 and day 80)
should have been undertaken [10]. Nonetheless, on
July 2007, the FDA’s Oncology Drugs Advisory Com-
mittee voted 7 to 2 that the level of evidence is not suf-
ficient, primarily because of failure to meet the main
study endpoint, to grant approval for orBec.
Presently, a randomized phase II study of BDP in
the prevention of aGVHD in patients undergoing
myeloablative allogeneic HSCT for hematologic can-
cer is underway The randomized, double-blinded trial
will enroll 138 patients, with 92 patients in the orBec
arm and 46 patients in the placebo arm. Treatment will
be administered in conjunction with a conditioning
regimen and will continue for 75 days after transplant.
The trial aims to determine if prophylactic administra-
tion of orBec can favorably influence the incidence
and severity of aGVHD, thereby decreasing the need
for high-dose systemic corticosteroid treatment.Budesonide (BUD)
BUD is a potent, nonhalogenated corticosteroid
that possesses a high ratio of topical-to-systemic activ-
ity compared with reference corticosteroids, including
BDP and prednisolone [18]. It undergoes rapid inacti-
vation by biotransformation in the liver producing low-
potency metabolites and hepatic clearance approach-
ing liver blood flow. BUD is metabolized by oxidation
through cytochrome P450 3A4 isoenzymes into inac-
tive metabolites; systemic availability is2.5 normal
in patients with moderate cirrhosis when compared to
healthy subjects [18]. Terminal half-life ranges be-
tween 3.6 to 4.5 hours [19]. Over the range of 3 to 15
mg/day, it displays linear pharmacokinetics [20]. The
dose-response curve inHSCTpatients has yet to be de-
termined. BUD may reduce bone marrow density, but
to a lesser degree than with traditional corticosteroid
therapy [18]. A higher incidence of moon face was
Biol Blood Marrow Transplant 15:395-405, 2009 399Nonabsorbable Corticosteroids Use in the Treatment of GI GVHDseen in Crohn’s disease patients on BUD than
placebo [18].
BUD is available in theUnited States as a controlled
ileal-release product (Entocort EC, Prometheus Lab-
oratory, SanDiego, CA). In healthy volunteers, the ma-
jority of controlled ileal-release BUD dissolves at pH
$5.5 so that 50% to 80% of an oral dose is absorbed
in the ileum and cecum [21]. Bioavailability ranged be-
tween 10.7% to 13.2% in Crohn’s disease patients and
healthy patients [18]. Using gamma camera and Indium
labeling, 69% of controlled-release BUD total dose
was taken up in the ileocolonic region [20]. That said,
it was suggested elsewhere that it may increase up to
21% in Crohn’s disease patients, only to decrease to
age-matched healthy individuals level following an 8-
week treatment course [19]. In several European coun-
tries, pH modified BUD (Budenofalk, Pharma
GmbH, Freiburg, Germany) is also available as a pH-
modified release pellet primed to release the drug at
pH $6, allowing delivery of the drug more distally
from the ileum up to the transverse colon [18]. BUD
is also available as an enema, which distributes up to
the left flexure and has a bioavailability of 15% in pa-
tients with distal ulcerative colitis or proctitis [20].
Studies in IBD showed that BUD (9 mg once daily) ef-
ficacy in the treatment of mild tomoderate Crohn’s dis-
ease in ileum and proximal colon was similar to
prednisolone (40 mg/day) and superior to mesalamine
in inducing remission; however, the duration of remis-
sion was not maintained for 1 year. BUD failed to pre-
vent recurrence after surgery for ileal/ileocecal
fibrostenotic fistula, but not for active disease surgery
[18,22].
Clinical Trials
pH-modified BUD was studied in $grade II
aGVHD patients who had undergone full myeloabla-
tive allogeneic transplant [23]. In addition to systemic
corticosteroids, 22 patients received the nonabsorb-
able corticosteroid and they were compared to 19 his-
toric controls. Onset of aGVHD was on day 130
(range: 10-310) and day1 38 (range: 15-73) for the in-
tervention and the control groups, respectively. The
decrease in stool volume and frequency of bowel
movement were the endpoints of intestinal GVHD
resolution. Patients with Glucksberg’s clinical grading
of I/II of lower tract represented 47% of the BUD arm.
Response was seen in 17 patients versus 6 patients
(77% versus 32%; P\ .01). In the BUD group, re-
sponder’s grade consisted of 9 patients with grade II,
5 patients with grade III, and 3 patients with grade
IV. Median time to improvement was similar between
the groups: 12 days (range: 3-28) versus 13 days (7018)
(P 5 ns). BUD was given for a median period of 24
days (range: 6-70 days). In 17 patients, it allowed
a fast taper of systemic corticosteroids at a median of
12 days (range: 6-25). BUD was also tapered in abouthalf of the patients who showed response. No aGVHD
relapses were seen when compared to the control
group. The only adverse event was the discovery of
C. glabrata on a routine stool culture in 1 patient. Based
on these findings, the authors advocated early initia-
tion of BUD in patients with aGVHD and to consider
BUD foam for rectal/sigmoidGVHD.This retrospec-
tive study included a heterogeneous GI GVHD pa-
tient population with different grades of GI aGVHD
with few patients with upper GI aGVHD. Moreover,
histologic GI GVHD grading was not complete in
the BUD arm. Analyses of response in different grade
GI GVHD subsets was not performed, hampering any
meaningful assessment of the efficacy of BUD in se-
vere grade GI GVHD. Last, the dose of systemic ste-
roids was increased when BUD was initiated in an
unspecified number of patients making it difficult to
solely ascribe efficacy and time to symptoms improve-
ment to BUD institution.
Recently, Andree et al. [24] retrospectively studied
oral BUD in 13 adult patients with GI cGVHD. Eight
patients had prior aGVHD but none had progressive
onset cGVHD. Nine patients received BUD as
a first-line single agent and 4 patients were given
BUD as second-line single agent. All patients (except
1 who received ileal-controlled release formulation)
received the pH-modified formulation at 3 mg 3 times
a day. BUDwas started at median of 238 (99-568 days)
and was given for amedian of 157 days (29-708 days) in
most patients. Eight patients (62%) patients
achieved complete remission of GI cGVHD. Four pa-
tients progressed with cGVHD following BUD dose
reduction. Of interest, some patients who had their
GI symptoms improved had a parallel improvement
in liver (n 5 3), lung (n 5 1), skin (n 5 2), and eyes
(n 5 2) cGVHD. That said, it is unclear how many
of those patients received BUD as a second-line agent.
Moreover, the absence of a control group precludes
firm conclusions that BUD exerts systemic immuno-
suppressive effect beyond its local action. Although ad-
renal function assessment was not specified, the
authors noted systemic corticosteroid side effects in 2
BUD patients who were underweight (\55 kg). Two
other patients experienced Clostridium difficile infec-
tion, and 1 patients had local viral enteritis during
BUD treatment.
Feng et al. [25] reported benefit following BUDand
tacrolimus in 2 pediatric patients withGIGVHD-asso-
ciated watery stools (500-800 mL/day). The formula-
tion, dose, or duration of therapy were not specified.
Other Nonabsorbable Corticosteroids
Betamethasone enema was used to treat systemic
corticosteroids-resistant GI GVHD affecting the rec-
tum and sigmoid colon (Grade II (n 5 2), Grade III
(n 5 4), Grade IV (n 5 2). The GI GVHD onset
ranged from day 117 to 1165 and the enema started
400 Biol Blood Marrow Transplant 15:395-405, 2009R. B. Ibrahim et al.shortly after (between day118 and 175) [8]. The dose
consisted of 100 mL daily (3.95 mg betamethasone so-
dium phosphate; 1 patient receiving 100 mL every 12
hours). The duration of treatment lasted for 5 to 27
days depending on clinical response. Six of 8 patients
responded as shown by improvement in diarrheal
and abdominal symptoms (1 patient was not evaluable
and another patient with stage IV did not respond).
The response persisted after stopping the enema,
thereby allowing discontinuation of systemic steroids.
Enema was well tolerated in 7 patients: 1 patient was
not able to continue owing to poor general condition.
An emergence of Streptococcus aureus, Pseudomonae aer-
uginosa, and Candida albicans was noted in 3 patients
without systemic infections, and it disappeared after
the end of treatment.
Local application of BUD oral solution at 3 mg
twice or thrice daily was beneficial in 12 patients
with refractory oral cGVHD [26]. Tixocortol pivalate
have been used for the local treatment of distal colitis
[27]. This poorly bioavailable corticosteroids, not
available in the United States, has yet to be evaluated
in the HSCT setting. Fluticasone proprionate has
been used in Crohn’s disease [27]; however, it was
found to be significantly inferior to prednisolone in
a controlled trial in Crohn’s disease [28].Unresolved Issues
Which is more effective: BUD versus BDP?
With the exception of the 2 trials with pH-modi-
fied BUD [23,24], most of the body of evidence in
HSCT is with BDP [11-15,17]. Assuming equal deliv-
ery to the site of action, it is unclear which compound
is more effective. Using a whole-blood lymphocyte
proliferation assay, in vitro BDP immunosuppressive
potency was superior to BUD [10]. Conversely, an
Italian study found that BUD (9 mg/day) was superior
to sustained-release oral BDP (10 mg/day) in the treat-
ment of mild to moderate Crohn’s disease affecting the
distal ileum and colon [29]. Furthermore, BDP is
a pro-drug that needs to metabolized to 17-BMP to
be metabolically active, whereas BUD is immediately
available after release. BUD is also metabolized 2 to
4 times faster than BDP [27]. The only formulation
of oral nonabsorbable BUD available in the United
States (ileal controlled release; Entecort EC) has yet
to be studied in HSCT.
The 2 BUD formulations (pH modified or ileal
controlled release) were equally effective at 9 mg daily
when they were used for the treatment of Irinotecan
and 5-Fluorouracil-induced diarrhea after loperamide
failure [30]. In the absence of head-to-head comparison
in HSCT or IBD, it cannot be said that these 2 formu-
lations are interchangeable [20]. In fact, systemic drug
exposure is less with the ileal-controlled release BUD,whereas there is absorption lag time of 2 hours with
the pH-release formulation [20].
Gastrointestinal acid suppression
The effect of acid suppression on BDP delivery to
its local site of action remains largely undefined. The
initial reports with BDP (using plain gelatin and en-
teric coated capsules) excluded patients actively receiv-
ing acid suppression therapy [11,12]. It is unclear if
acid suppression intake was an exclusion criteria in
the 2 studies using BDP oil emulsion [13,14] or with
pH modified BUD [23,24]. In addition, proton pump
inhibitors have been shown to counfound the diagnosis
of biopsy-proven gastric GVHD, the indication for
BDP therapy [31]. Ileal controlled-release BUD phar-
macokinetics is independent of gastric pH, and not af-
fected by acid suppressive therapy such as cimetidine
or omeprazole [18,19].
Another dilemma is the influence of nonabsorb-
able corticosteroids on the GI microflora, which can
be compounded by gastric suppression. Reports with
BDP [11,15], BUD [23,24], and betamethasone enema
[15] in HSCT patients hinted at an increase in micro-
bial colonization, although the clinical implications re-
main to be seen. Gastric suppression primarily affects
the stomach and proximal small intestine and an al-
tered microflora of the upper gut is commonly ob-
served [32]. Medications that suppress gastric acid
have been associated with microbial colonization of
the normally sterile upper GI tract, with altered
gastrointestinal flora and increased susceptibility to in-
fectious gastroenteritis [33], Clostridium difficile-associ-
ated disease [34], and community acquired pneumonia
[35-37].
An unhealthy GI tract exhibits luminal pH distri-
bution distinctly different from a healthy 1, because
of alteration in the colonic microflora generating
compounds that affect colonic pH [21,27]. In addition,
the role of colonic bacteria maybe hampered by
antibiotics. Other factors affecting gut pH are
nonabsorbable disaccharides (eg, lactulose) and bowel
preparation before colonoscopy. On balance, HSCT
patients are invariably exposed to all of the above fac-
tors at some point during their GI GVHD course, and
it follows that knowledge of luminal pH changes in
GVHD is instrumental in ensuring adequate delivery
of nonabsorbable corticosteroids therapy.
Optimal drug delivery
Transport to and drug delivery at the proposed
site of GI epithelium inflammation are both complex
processes. Interindividual variabilities in gastric
emptying, intestinal transit time, orocecal transit
time, intraluminal pH, disease pattern, drug disposi-
tion (colon arrival, dose dumping) and drug GI mu-
cosal concentration account for the wide range of
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[20]. Bisacodyl and promotility agents (eg, metoclo-
pramide), by virtue of their effect on transit time,
can reduce the systemic absorption of 5-aminosali-
cylic acid preparations in IBD patients [20,21].
The activity of nonabsorbable corticosteroids in
the face of GI GVHD-associated severe diarrhea
has yet to be tested as the majority of BDP studies
excluded patients with severe diarrhea [13,15,17].
Baehr et al. [11] noted that with possible better re-
sponse in upper GI GVHD with BDP than lower
GI GVHD. Castilla et al. [10] reported a trend to-
ward less response with BDP in a GI GVHD cohort
with diarrhea. Noteworthy, in reports assessing
BUD in the treatment of chemotherapy-induced di-
arrhea, early initiation was deemed to play a crucial
role, because prolonged and more severe diarrhea
may limit the intestinal contact time of the product
[30,38].
Upper GI GVHD-associated bleeding is 6% [39].
Most of the bleeding is because of areas of mucosal de-
fect of the involved bowel, most commonly the distal
small bowel and the cecum [39]. As discussed early,
the latter segments are the site of drug delivery for con-
trolled-release absorbable corticosteroids, at least in
IBD patients. At present, the efficacy of nonabsorbable
corticosteroids in GVHD-induced bleeding has not
been thoroughly examined.
Inflammation had little impact on small intestine
transit time, but more influence on colon transit, nota-
bly the distal segments [19,21]. Studies in IBD have
shown that the transit characteristics in the colon are
so unpredictable that adequate amount of the drug to
reach the inflamed tissues may not be possible,
especially at the descending colon level [27]. Indeed,
pH-modified BUD appeared relatively ineffective in
patients with Crohn’s disease confined to the left colon
and rectum, in whom colonic pH may be low [21].
However, an 18-mg dose of pH-modified BUD fared
better than 6 mg daily in tranverse colon to rectal dis-
ease [28]. This has been attributed to slower release
properties of the pH-modified BUD (when compared
to ileal-controlled release BUD). In all, enhancing the
local bioavailability of BUD in the colon using higher
doses, especially the distal segments, has been recom-
mended [27].
In Crohn’s disease patients, systemic availability of
ileal-controlled release BUD was unchanged (12%)
without appreciable difference between the fasted
and fed state, and this accounting for the physiologic
emptying delay of 1 to 2 hours caused by food [19].
pH-modified BUD is usually taken 30 minutes before
meals [28]. The absorption of these compounds in pa-
tients with extensive bowel resection remains ill de-
fined. In 1 report, Crohn’s disease patients receiving
pH-modified BUDwith a history of small bowel resec-
tions exceeding $80 cm were excluded [40].Optimal dosing regimen
The optimal BDP or BUD dose has yet to be de-
fined. McDonald et al. [10] speculated that BDP at 8
mg/day may not be the maximally tolerated dose in
HSCT patients. Outside the HSCT setting, BDP 5
mg twice daily  12 weeks (then once daily for 12
weeks) was helpful in distal ileum and ileal-right co-
lonic localization mild to moderate crohn’s disease
[41]. A dose of oral BDP at 6 mg/daily was effective
in a case report of an adult with idiopathic lymphocytic
enterocolitis [42]. A dose-response curve for BUD has
been noted in the setting of IBD where maintenance
doses $9 mg/day of either controlled-release or pH-
modified BUD was better than lower doses, especially
in patients with high disease activity [28,40]. In fact,
BUD dosing in Crohn’s disease ranged from 9 to 18
mg/day, with the higher dose being more effective
for descending colon and sigmoid segments disease
[19,28,43].
As far as dosing frequency is concerned, BUD once
daily is feasible owing to its long retention in gut mu-
cosa [19]. Once-daily administration of controlled-re-
lease BUD has been advocated to be equally effective
to divided dose [19,44] or even better than twice daily
regimen [45]. Indeed, this regimen achieved remission
more quickly than twice-daily administration and at
a rate similar to that with prednisolone [18]. Nonethe-
less, as stated previously, it is still advisable to admin-
ister the drug in divided doses when distal sites of
inflammation are involved, as it will increase the likeli-
hood that adequate amounts of drug is available in
a segments where transit patterns are variable [20].
Response stratified by injured bowel segments has
yet to undertaken in HSCT. This is of great impor-
tance because, for instance, the development of
aGVHD-related diarrhea is mainly attributed to
GVHD of the small intestine [46].
Adrenal suppression with nonabsorbable cortico-
steroids does occur, albeit at lesser degree than sys-
temic corticosteroids [18,28]. More depression in
a random cortisol level was seen with BUD 18 mg/
dose at the 6-week mark in Crohn’s disease patients
than lower doses, supporting a dose-dependent effect
[18,28]. Log-linear regression revealed that BUD at
29 mg/day was comparable to 20 mg/day of predniso-
lone in healthy individuals [19]. Most reports in
HSCT found that BUD and BDP suppress the adrenal
function, asmeasured byACTHsuppression test in the
majority of cases [11,14]. The clinical significance of
the biochemical adrenal suppression findings is un-
clear, as patients were asymptomatic and most has
been exposed to systemic corticosteroids at prior time
points [11,14].
In Crohn’s disease, ileal-controlled release BUD
has been evaluated in pediatric patients ranging
between 9 and 14 years at 9 mg/day [19,20]. Body-
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life was reduced to 1.9 hours in these patients. BUD’s
efficacy and safety was similar to adults with active
Crohn’s disease [19,20]. Escher et al. reported
controlled-release BUD efficacy at 9 mg/day in 48
children (range: 6-16 years) with active Crohn’s dis-
ease with relatively better safety profile than systemic
corticosteroids. Although most reports in HSCT
hint at the administration of BDP [11,14,17] and
BUD [23] in pediatric patients (Table 1), no formal
pharmacokinetic, efficacy, and safety data is available
in this patient population, and it follows that their
use in this group should be considered experimental.
Being a CYP450 3A4 substrate, BUD can be af-
fected by inhibitors of this pathway. Ketoconazole
200 mg once daily  3 days increased ileal-controlled
release BUD (3 mg/day) systemic exposure by7-fold
[19]. The magnitude of this interaction was reduced by
50%when BUDwas given 12 hours prior to ketocona-
zole. Cushinoid symptoms were attributed to a sus-
pected BUD-amiodarone CYP450 3A4 substrate
competition [48]. In another case, BUD-induced toxic
hepatitis in a HIV patient was felt to result from rito-
navir inhibition of BUD metabolism [49]. HSCT pa-
tients are invariably exposed to CYP450 3A4
inhibitors such as triazole antifungals, which can lead
to higher than anticipated systemic drug exposure
[50,51]. In the 2 reports assessing pH modified BUD
salutary effect in GI GVHD, it is uncertain if the pres-
ence of BUD metabolic inhibitors was factored in the
analyses [23,24].Efficacy end points
The primary efficacy endpoint assessing nonab-
sorbable corticosteroids in HSCT varied considerably
(Table 1). Complicating any meaningful analysis was
the lack of prospective validation of these endpoints
prior to the study intervention. Few studies included
nonmyeloablative HSCT patients [13,17]. This is
not without implication because the widely used grad-
ing system for aGVHD validated in the full myelo-
ablative HSCT setting has yet to be validated in
nonmyeloablative HSCT, with its characteristic late-
onset aGVHD [52]. Moreover, GI morbidity seems
to be more severe in nonmyeloablative patients versus
their myeloablative counterparts between 6 and 12
months [52]. Recently, the consensus (Glucksberg)
criteria for GI GVHD were put into question, as
they fail to quantify burden of disease over time, its
impact on outcome, and do not account for time to re-
sponse to treatment [53]. An aGVHD activity index
based upon the severity of upper gut symptoms,
much like Crohn’s disease activity index, was sug-
gested in full myeloablative HSCT [53]. Given the
proved track record of nonabsorbable corticosteroids
(chiefly BUD) in Crohn’s disease, adapting this indexto investigations of these agents in HSCT is worth-
while.
Although response in the IBD setting was typically
performed at the 8-week mark, data in HSCT is some-
what more heterogeneous. This is likely because of the
wide range of clinical presentation of GI GVHD and
nonstandardized study endpoints. For instance, the
observation that BDP onset of action was 1 to 2 weeks
led to the design of trials assessing a 10-day induction
course of BDP and oral prednisone [11,12,17]. Other
reports did not set a timeline for response, and, hence,
onset of action varied from to 3 to 28 days (Table 1)
[13,23,24]. Emerging evidence suggests that GI
GVHD disease is a progressive condition, and that
early recognition and intervention may significantly
improve outcome [54]. Indeed, because the incidence
of upper GI is 22% and it predates lower GI GVHD,
it follows that early treatment with upper GI may
lead to a high response rate of grade I GVHD and po-
tentially avert progression to grade II GI GVHD [4].
Not withstanding the lack of standard GI GVHD re-
sponse across BUD/BDP trials in HSCT, current evi-
dence would suggest benefit of this strategy in patients
with upper GI symptoms [11-14]. That said, the meth-
odologic inconsistencies of these trials are such that
further exploration of the impact of early BUD or
BDP intervention is still warranted.
In keeping with the changing face of GI complica-
tions in HSCT over the last 2 decades and advance-
ment in supportive care [37], response to
nonabsorbable corticosteroids should be constantly
put into perspective. Recently, response to a 5-day
methylprednisolone (2 mg/kg/day) in the treatment
of aGVHDwas proposed to predict transplant-related
mortality [4]. Diarrhea volume exceeding 500 mL in
the week after stem cell infusion has been suggested
to be forecast the severity of aGVHD, and, therefore,
may allow tailoring prophylaxis to the needs of each
patient [55]. This strategy may allow intervention at
the time of peak tissue cytokine release. Similarly, an
increase in TNF-a during conditioning regimen has
been correlated with the development of GVHD
[56,57]. Serum citrulline-based [58,59] and capsule
endoscopy [60] as gut injury predictors have been pro-
posed. Gut disease was considered improved if there
was resolution of diarrhea or decrease in the 3 day av-
erage stool volume by 500 mL with clearing of cramps
and bleeding if present [61,62]. Alternatively, progres-
sive gut disease was defined as an increase in the 3-day
average stool volume by 2.5 L or the development of
new cramps or bleeding [61,62]. Taken together, an
individualized approach with nonabsorbable cortico-
steroids incorporating some or all of these discussed
factors is an appealing concept, especially because in
theory, local GI GVHD treatment should not inter-
fere with graft-versus-tumor effect in contrast to sys-
temic immunosuppressants [63].
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More than a decade has gone by since the seminal
work of Baehr et al. [11], where BDP was first de-
scribed in HSCT patients. Subsequent reports have
shown some benefit of the nonabsorbable corticoste-
roids. Their use continues because of the lack of ef-
fective GI GVHD treatment, not because of the
robustness of nonabsorbable corticosteroids data in
HSCT [5]. In fact, this review argues that the body
of evidence is fraught with methodologic inconsis-
tencies, and it leaves more questions unanswered.
Drawing on the example of IBD, future research
will need to ensure that these agents reach their in-
tended site of action in the HSCT recipient, and, in
hindsight, this should have predated efficacy under-
takings. Transplanters are still grappling with the ba-
sic pharmacokinetic data of BUD or BDP in their
population.
On a positive note, given the well-established dis-
cordance between endoscopic, clinical, and, histologic
GI GVHD findings [46,64,65], prophylactic strategies
with this agents are justified and are laudably being
pursued. The anticipated protracted exposure to these
agents will also shed light on their long-term safety.
The report of benign intracranial hypertension with
BUD in 3 pediatric patients with Crohn’s disease is
a case in point [66]. Alternatively, nonabsorbable
corticosteroids should merit consideration as a ‘‘ste-
roid-sparing’’ strategy, and diarrhea or GI bleeding re-
solve so as to maximize contact to the GI mucosa.
Until now, data in HSCT showing a potential of
BUD or BDP in reducing systemic corticosteroids
dose is cursory at best [14,17,23]. Only the collabora-
tion of multiple transplant centers in the investigation
of all available molecules and the use of a unified
definition of response will help delineate the role of
nonabsorbable corticosteroids in transplant.ACKNOWLEDGMENTS
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